IQVIA (NYSE:IQV) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

Other research analysts also recently issued research reports about the stock. UBS Group dropped their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Citigroup decreased their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Performance

Shares of IQV opened at $185.47 on Wednesday. The company has a market capitalization of $32.70 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA has a one year low of $179.28 and a one year high of $261.72. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company’s fifty day moving average price is $197.14 and its 200 day moving average price is $211.59.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts expect that IQVIA will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently added to or reduced their stakes in the company. Mattson Financial Services LLC lifted its holdings in IQVIA by 20.9% during the 4th quarter. Mattson Financial Services LLC now owns 5,844 shares of the medical research company’s stock valued at $1,148,000 after purchasing an additional 1,011 shares during the last quarter. Siemens Fonds Invest GmbH raised its stake in shares of IQVIA by 973.2% in the fourth quarter. Siemens Fonds Invest GmbH now owns 21,345 shares of the medical research company’s stock worth $4,195,000 after acquiring an additional 19,356 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of IQVIA in the fourth quarter worth about $25,152,000. Forum Financial Management LP raised its stake in shares of IQVIA by 53.2% in the fourth quarter. Forum Financial Management LP now owns 2,067 shares of the medical research company’s stock worth $406,000 after acquiring an additional 718 shares during the last quarter. Finally, Toronto Dominion Bank raised its stake in shares of IQVIA by 2.2% in the fourth quarter. Toronto Dominion Bank now owns 61,774 shares of the medical research company’s stock worth $12,139,000 after acquiring an additional 1,358 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.